Your browser doesn't support javascript.
Preservation of neutralizing antibody function in COVID-19 convalescent plasma treated using a riboflavin and ultraviolet light-based pathogen reduction technology.
Yonemura, Susan; Hartson, Lindsay; Dutt, Taru S; Henao-Tamayo, Marcela; Goodrich, Raymond; Marschner, Susanne.
  • Yonemura S; Terumo Blood and Cell Technologies, Lakewood, CO, USA.
  • Hartson L; Infectious Disease Research Center, Colorado State University, Fort Collins, CO, USA.
  • Dutt TS; Department of Microbiology, Immunology & Pathology, Colorado State University, Fort Collins, CO, USA.
  • Henao-Tamayo M; Department of Microbiology, Immunology & Pathology, Colorado State University, Fort Collins, CO, USA.
  • Goodrich R; Infectious Disease Research Center, Colorado State University, Fort Collins, CO, USA.
  • Marschner S; Terumo Blood and Cell Technologies, Lakewood, CO, USA.
Vox Sang ; 116(10): 1076-1083, 2021 Nov.
Article in English | MEDLINE | ID: covidwho-1515248
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
BACKGROUND AND

OBJECTIVES:

Convalescent plasma (CP) has been embraced as a safe therapeutic option for coronavirus disease 2019 (COVID-19), while other treatments are developed. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is not transmissible by transfusion, but bloodborne pathogens remain a risk in regions with high endemic prevalence of disease. Pathogen reduction can mitigate this risk; thus, the objective of this study was to evaluate the effect of riboflavin and ultraviolet light (R + UV) pathogen reduction technology on the functional properties of COVID-19 CP (CCP). MATERIALS AND

METHODS:

COVID-19 convalescent plasma units (n = 6) from recovered COVID-19 research donors were treated with R + UV. Pre- and post-treatment samples were tested for coagulation factor and immunoglobulin retention. Antibody binding to spike protein receptor-binding domain (RBD), S1 and S2 epitopes of SARS-CoV-2 was assessed by ELISA. Neutralizing antibody (nAb) function was assessed by pseudovirus reporter viral particle neutralization (RVPN) assay and plaque reduction neutralization test (PRNT).

RESULTS:

Mean retention of coagulation factors was ≥70%, while retention of immunoglobulins was 100%. Starting nAb titres were low, but PRNT50 titres did not differ between pre- and post-treatment samples. No statistically significant differences were detected in levels of IgG (P ≥ 0·3665) and IgM (P ≥ 0·1208) antibodies to RBD, S1 and S2 proteins before and after treatment.

CONCLUSION:

R + UV PRT effects on coagulation factors were similar to previous reports, but no significant effects were observed on immunoglobulin concentration and antibody function. SARS-CoV-2 nAb function in CCP is conserved following R + UV PRT treatment.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study Limits: Humans Language: English Journal: Vox Sang Year: 2021 Document Type: Article Affiliation country: Vox.13108

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study Limits: Humans Language: English Journal: Vox Sang Year: 2021 Document Type: Article Affiliation country: Vox.13108